Publication: Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
Issued Date
2012-05-01
Resource Type
ISSN
14602091
03057453
03057453
Other identifier(s)
2-s2.0-84859609445
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Antimicrobial Chemotherapy. Vol.67, No.5 (2012), 1217-1223
Suggested Citation
Pauline Byakika-Kibwika, Mohammed Lamorde, Violet Okaba-Kayom, Harriet Mayanja-Kizza, Elly Katabira, Warunee Hanpithakpong, Nadine Pakker, Thomas P C Dorlo, Joel Tarning, Niklas Lindegardh, Peter J. de vries, David Back, Saye Khoo, Concepta Merry Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. Journal of Antimicrobial Chemotherapy. Vol.67, No.5 (2012), 1217-1223. doi:10.1093/jac/dkr596 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/14832
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults
Abstract
Background: Treatment of HIV/malaria-coinfected patients with antiretroviral therapy (ART) and artemisinin-based combination therapy has potential for drug interactions. We investigated the pharmacokinetics of artemether, dihydroartemisinin and lumefantrine after administration of a single dose of 80/480 mg of artemether/lumefantrine to HIV-infected adults, taken with and without lopinavir/ritonavir. Methods: A two-arm parallel study of 13 HIV-infected ART-naive adults and 16 HIV-infected adults stable on 400/100 mg of lopinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors (ClinicalTrials.gov, NCT 00619944). Each participant received a single dose of 80/480 mg of artemether/lumefantrine under continuous cardiac function monitoring. Plasma concentrations of artemether, dihydroartemisinin and lumefantrine were measured. Results: Co-administration of artemether/lumefantrine with lopinavir/ritonavir significantly reduced artemether maximum concentration (C max ) and area under the concentration-time curve (AUC) [median (range): 112 (20-362) versus 56 (17-236) ng/mL, P = 0.03; and 264 (92-1129) versus 151 (38-606) ng · h/mL, P < 0.01]. Dihydroartemisinin C max and AUC were not affected [66 (10-111) versus 73 (31-224) ng/mL, P = 0.55; and 213 (68-343) versus 175 (118-262) ng · h/mL P = 0.27]. Lumefantrine C max and AUC increased during co-administration [2532 (1071-5957) versus 7097 (2396-9462) ng/mL, P < 0.01; and 41 119 (12 850-125 200) versus 199 678 (71 205-251 015) ng · h/mL, P < 0.01]. Conclusions: Co-administration of artemether/lumefantrine with lopinavir/ritonavir significantly increases lumefantrine exposure, but decreases artemether exposure. Population pharmacokinetic and pharmacodynamic trials will be highly valuable in evaluating the clinical significance of this interaction and determining whether dosage modifications are indicated. © The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
